Earnings Tell The Story For KPC Pharmaceuticals,Inc (SHSE:600422)

KPC Pharmaceuticals,Inc's (SHSE:600422) price-to-earnings (or "P/E") ratio of 36.6x might make it look like a sell right now compared to the market in China, where around half of the companies have P

Simply Wall StApr 22 20:20 ET

China Resources Pharmaceutical (03320.HK): KPC achieved total revenue of 1,853 billion yuan in the first quarter

Gelonghui, April 22 | China Resources Pharmaceutical (03320.HK) announced that in the first quarter of 2024, KPC achieved total operating revenue of 1,853 billion yuan, a decrease of 3% year on year; net profit of 121 million yuan, a decrease of 10% year on year.

Gelonghui FinanceApr 21 20:14 ET

Kunming Pharmaceutical Group (600422.SH) reported first-quarter results, net profit of 119 million yuan, a year-on-year decrease of 9.41%

Kunming Pharmaceutical Group (600422.SH) released its report for the first quarter of 2024. The company achieved operating revenue during the reporting period...

Zhitong FinanceApr 19 06:06 ET

Kunyao Group Receives Clinical Trial Approval for FMF Drug

China's National Medical Products Administration has approved Kunyao Group's (SHA:600422) plan to carry out a clinical trial of its drug against familial Mediterranean fever of FMF, according to a Wed

MT NewswiresApr 16 22:51 ET

Kunming Pharmaceutical Group (600422.SH): “KPC-149 Oral Solution” approved to carry out related clinical trials

Kunming Pharmaceutical Group (600422.SH) announced that the company recently received KPC- issued by the State Drug Administration...

Zhitong FinanceApr 16 06:07 ET

Kunming Pharmaceutical Group (600422.SH): Obtained Drug Clinical Trial Approval Notice

Gelonghui, April 16 | Kunming Pharmaceutical Group (600422.SH) announced that the company recently received the “Drug Clinical Trial Approval Notice” for the KPC-149 oral solution (Notification Number: 2024LP00909, referred to as “the new drug”) from the State Drug Administration in accordance with Class 2.2 improved new drug, and agreed to carry out related clinical trial research on the new drug. KPC-149 oral solution is a Class 2.2 improved new drug developed by the company. The indications are: Familial Mediterranean Fever.

Gelonghui FinanceApr 16 05:56 ET